4月6日 - ** 生物技术公司Praxis Precision Medicines PRAX.O股价盘前上涨4.7%至325美元
** 该公司称其实验性药物elsunersen可减少一种罕见的儿童癫痫的发作；SCN2A-DEE是一种遗传性脑部疾病，在生命早期就开始发作，导致频繁、难以治疗的癫痫发作。
** 公司称，对九名儿童进行的早期研究显示，与安慰剂相比，每月癫痫发作次数减少了 77%
** 称71%接受治疗的儿童在6个月后癫痫发作减少了一半以上，疗效可持续一年之久
** 补充说，儿童在睡眠、运动、肌肉张力和注意力方面也有改善；未发现严重的安全问题
** 表示正在进行更大规模的试验，并将在科学会议上分享更多数据
** 截至上次收盘，该公司股价年累计上涨约 5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.